Aileron Therapeutics Inc./$RNTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Aileron Therapeutics Inc.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
- Ticker
- $RNTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 10
- Headquarters
- Austin, United States
- Website
- www.reintx.com
RNTX Metrics
BasicAdvanced
$52M
-
-$0.58
1.37
-
Price and volume
Market cap
$52M
Beta
1.37
52-week high
$2.10
52-week low
$0.54
Average daily volume
421K
Financial strength
Current ratio
4.27
Quick ratio
4.187
Profitability
EBITDA (TTM)
-20.757
Effective tax rate (TTM)
1.41%
Management effectiveness
Return on assets (TTM)
-21.02%
Return on equity (TTM)
-96.42%
Valuation
Price to book
5.1
Price to tangible book (TTM)
-5.4
Price to free cash flow (TTM)
-2.76
Free cash flow yield (TTM)
-36.23%
Free cash flow per share (TTM)
-0.22
Growth
Earnings per share change (TTM)
-78.05%
3-year earnings per share growth (CAGR)
-46.78%
10-year earnings per share growth (CAGR)
-51.24%
RNTX Financial Performance
Revenues and expenses
RNTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.